Headache News and Research RSS Feed - Headache News and Research

In medicine a headache or cephalalgia is a symptom of a number of different conditions of the head. Some of the causes are benign while others are medical emergencies.
Further Reading
Inflammation plays causal role in neurologic changes associated with Lyme disease

Inflammation plays causal role in neurologic changes associated with Lyme disease

About 15% of patients with Lyme disease develop peripheral and central nervous system involvement, often accompanied by debilitating and painful symptoms. New research indicates that inflammation plays a causal role in the array of neurologic changes associated with Lyme disease, according to a study published in The American Journal of Pathology. [More]
Baxter submits BAX 855 NDA to Japan's MHLW for treatment of hemophilia A patients

Baxter submits BAX 855 NDA to Japan's MHLW for treatment of hemophilia A patients

Nektar Therapeutics reported today that partner Baxter International Inc. announced that the company has submitted a new drug application (NDA) to Japan's Ministry of Health, Labour and Welfare for the approval of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment based on ADVATE [Antihemophilic Factor (Recombinant)] for patients over 12 years of age with hemophilia A. [More]
Eisai, Arena complete two Phase 1 registrational trials for once-daily formulation of lorcaserin

Eisai, Arena complete two Phase 1 registrational trials for once-daily formulation of lorcaserin

Eisai Inc. and Arena Pharmaceuticals, Inc. today announced the completion of two Phase 1 registrational clinical trials that Eisai and Arena believe demonstrate bioequivalence of an investigational once-daily extended release formulation of lorcaserin, as compared to the twice-daily immediate release formulation approved by the US Food and Drug Administration and marketed as BELVIQ. [More]
New simeprevir clinical data to be presented at EASL's International Liver Congress 2015

New simeprevir clinical data to be presented at EASL's International Liver Congress 2015

Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, today announced that clinical data for simeprevir, its NS3/4A protease inhibitor for the treatment of hepatitis C virus (HCV) infection, will be presented at The International Liver Congress 2015 of the European Association for the Study of the Liver taking place in Vienna from April 22-26. [More]
Study examines new Ebola Prediction Score

Study examines new Ebola Prediction Score

Abdominal pain, fever and unexplained bleeding - which are commonly believed to indicate infection with the Ebola virus -- are not significantly predictive of the disease, according to the results of a study examining a new Ebola Prediction Score published online Friday in Annals of Emergency Medicine ("Derivation and Internal Validation of the Ebola Prediction Score for Risk Stratification of Patients with Suspected Ebola Virus Disease"). [More]
Rhode Island Hospital physician comes up with new diagnostic tool for Ebola virus

Rhode Island Hospital physician comes up with new diagnostic tool for Ebola virus

Adam C. Levine, M.D., an emergency medicine physician at Rhode Island Hospital and The Miriam Hospital who treated Ebola-infected patients in Liberia last year, used his field experience to create a tool to determine the likelihood that patients presenting with Ebola symptoms will actually carry the virus. [More]
Astellas Pharma, Medivation announce topline results from enzalutamide Phase 2 STRIVE trial

Astellas Pharma, Medivation announce topline results from enzalutamide Phase 2 STRIVE trial

Astellas Pharma Inc. and Medivation, Inc. today announced topline results from the Phase 2 STRIVE trial comparing enzalutamide with bicalutamide in a study population of men with non-metastatic or metastatic castration-resistant prostate cancer. [More]
Shire announces availability of Natpara (parathyroid hormone) for injection in U.S.

Shire announces availability of Natpara (parathyroid hormone) for injection in U.S.

Shire plc today announced that Natpara (parathyroid hormone) for injection is now available in the United States. The U.S. Food and Drug Administration approved Natpara as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism on January 23, 2015. [More]
Merck announces availability of GARDASIL 9 HPV vaccine in Canada

Merck announces availability of GARDASIL 9 HPV vaccine in Canada

Merck, known as MSD outside the United States and Canada, announced today that GARDASIL 9 (Human Papillomavirus 9-valent Vaccine, Recombinant), Merck's 9-valent human papillomavirus (HPV) vaccine, is now available in Canada. [More]
MOVANTIK (naloxegol) now available in U.S. for treatment of OIC in adult patients with non-cancer pain

MOVANTIK (naloxegol) now available in U.S. for treatment of OIC in adult patients with non-cancer pain

Nektar Therapeutics reported that partner AstraZeneca announced today that MOVANTIK (naloxegol) has launched in the United States. On September 16, 2014, the US Food and Drug Administration (FDA) approved MOVANTIK as the first once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of opioid-induced constipation (OIC) in adult patients with chronic, non-cancer pain. [More]
ElectroCore selected as finalist in ‘Technology’ category at FT ArcelorMittal Boldness in Business awards

ElectroCore selected as finalist in ‘Technology’ category at FT ArcelorMittal Boldness in Business awards

At the annual FT ArcelorMittal Boldness in Business awards held in London last week electroCore was one of six finalists in the ‘Technology’ category, in a competition that included over 250 companies, which Open Garden won for its FireChat digital app. [More]
Hospira announces availability of INFLECTRA (infliximab) in Canada

Hospira announces availability of INFLECTRA (infliximab) in Canada

Hospira, Inc., a global leader in biosimilars and the world's leading provider of injectable drugs and infusion technologies, announces the availability of INFLECTRA (infliximab) in Canada, the country's first subsequent entry biologic (SEB) monoclonal antibody (mAb) therapy. [More]
FDA approves Quadracel vaccine to protect young children from life-threatening diseases

FDA approves Quadracel vaccine to protect young children from life-threatening diseases

Sanofi Pasteur, the vaccines division of Sanofi, announced today that the U.S. Food and Drug Administration has approved use of Quadracel (Diphtheria and Tetanus Toxoids and Acellular Pertussis Absorbed and Inactivated Poliovirus; DTaP-IPV) vaccine for active immunization against diphtheria, tetanus, pertussis and poliomyelitis in children 4 through 6 years of age. [More]
IV cosyntropin therapy matches EBP in relieving pain from post-dural puncture headache

IV cosyntropin therapy matches EBP in relieving pain from post-dural puncture headache

Intravenous (IV) cosyntropin therapy was equivalent to epidural blood patch (EBP) in relieving pain from post-dural puncture headache (PDPH) with potential for fewer complications and lower costs, data from a randomized, controlled trial showed. [More]
Egalet announces plans to commercialize SPRIX Nasal Spray and OXAYDO tablets

Egalet announces plans to commercialize SPRIX Nasal Spray and OXAYDO tablets

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced its plans for the commercialization of SPRIX (ketorolac tromethamine) Nasal Spray and OXAYDO (oxycodone HCI, USP) tablets for oral use only –CII. [More]
Migraine headaches with auras may increase risk of stroke

Migraine headaches with auras may increase risk of stroke

People who suffer migraine headaches with auras are at roughly double the risk of suffering the most common type of stroke. [More]
Patients with carpal tunnel syndrome twice as likely to have migraine headaches, shows study

Patients with carpal tunnel syndrome twice as likely to have migraine headaches, shows study

Patients with carpal tunnel syndrome are more than twice as likely to have migraine headaches, reports a study in Plastic and Reconstructive Surgery--Global Open, the official open-access medical journal of the American Society of Plastic Surgeons (ASPS). [More]
Glyxambi for Type 2 diabetes treatment now available by prescription across the U.S.

Glyxambi for Type 2 diabetes treatment now available by prescription across the U.S.

Glyxambi® (empagliflozin/linagliptin) tablets are now available by prescription in many leading chain and independent pharmacies across the U.S., including Walgreens and Rite Aid. [More]
Study finds no added benefit from sipuleucel-T in men with metastatic prostate cancer

Study finds no added benefit from sipuleucel-T in men with metastatic prostate cancer

Sipuleucel-T (trade name Provenge) has been approved since September 2014 for men with metastatic prostate cancer who have few or no symptoms and do not yet require chemotherapy. In the dossier assessment conducted by the German Institute for Quality and Efficiency in Health Care (IQWiG) in January 2015, no added benefit could be derived for sipuleucel-T. [More]
AAPM announces recipients of 2015 Pain Medicine Fellowship Excellence Award

AAPM announces recipients of 2015 Pain Medicine Fellowship Excellence Award

The American Academy of Pain Medicine is pleased to announce its 2015 Pain Medicine Fellowship Excellence Award Recipients in recognition of a Pain Medicine Fellowship Program that provides an exceptional learning experience to its fellows, preparing them to deliver the highest standard of care to patients with pain. [More]
Advertisement